Lantern Pharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Lantern Pharma generated cash of -$14,346,548, which is less than the previous year. Cash used in financing activities reached the amount of -$499,997 last year. Net change in cash is therefore -$15,805.
Cash Flow
| 2018 | -1.27M | 5.33K | 535K |
|---|---|---|---|
| 2019 | -2.12M | -5.71K | 2.92M |
| 2020 | -5.65M | -16.13K | 23.66M |
| 2021 | -10.59M | -19.53M | 63.41M |
| 2022 | -12.76M | 179.26K | -2.18K |
| 2023 | -14.34M | -930.21K | -499.99K |
LTRN Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 37.74M | 52.52M | 19.22M | 1.23M | 445.16K | 1.17M |
Operating activities | ||||||
Net income | -15.96M | -14.25M | -12.36M | -5.90M | -2.42M | -1.72M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 14.61K | 10.08K | 6.76K | 3.38K | 1.62K | -2.54K |
Stock-based compensation expense | 1.06M | 1.18M | 961.54K | 1.19M | 117.76K | 0 |
| Deferred income tax benefit | 1.06M | 1.18M | 961.54K | 1.19M | 117.76K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | -158.40K | -71.65K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 580.35K | 1.62M | 117.16K | 372.66K | 0 |
Cash generated by operating activities | -14.34M | -12.76M | -10.59M | -5.65M | -2.12M | -1.27M |
Investing activities | ||||||
Purchases Of Investments | 0 | -3.91M | -19.57M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -18.73K | -27.84K | -15.49K | -16.13K | -5.71K | 0 |
Acquisitions Net | 0 | -179.26M | 19.53B | 0 | 0 | 0 |
Cash generated by investing activities | -930.21K | 179.26K | -19.53M | -16.13K | -5.71K | 5.33K |
Financing activities | ||||||
Common Stock Issued | 0 | 0 | 68.99M | 23.55M | 2.92M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -499.99K | -2.48M | -939.66K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -169.04K | 0 | 0 |
Cash used in financing activities | -499.99K | -2.18K | 63.41M | 23.66M | 2.92M | 535K |
Net Change In Cash | -15.80K | -14.78M | 33.29M | 17.99M | 786.86K | -731.18K |
Cash at end of period | 21.93M | 37.74M | 52.52M | 19.22M | 1.23M | 445.16K |
| Data source | Data source | Data source | Data source |